Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon Sep 05, 2012 9:43am
335 Views
Post# 20318825

RE: RE: Shakeup.

RE: RE: Shakeup.

This move happened sooner than I expected, but good on the board to execute a management change before we enter 2013. At the end of the day this move was all about the share price (there's a reason why "shareholder value" was mentioned throughout the press release). SK lost credibility with investors and the street to the point where a change was needed. The focus now will be on rebuilding that credibility & achieving growth in profit. Having one of our largest shareholders with a few grey hairs lead the company will be veiwed as a positive.

 

It is possible that the company is now tracking below the guided 10% growth. But the street won't care anymore with a new sherriff in town. All prior guidance of any sort is now void. I think ultimately the company will execute some operational changes, drop non-core products (potentially Earthworks), and try to drive a very positive 2013 so as to get buy-in from investors that indeed things are different. I also think if the share price moves up sufficiently enough the BOD would consider a sale of the business. One has to think that Richard is not wanting to be in his new role for the long-term. Rather I suspect he wants to lead the turn around effort, be a credible face for the company, and ultimately sell. North of $2.00 in share price will be needed (at least). That's too high a premium today,so no sale for the meantime.

Bullboard Posts